Elanco Animal Health (ELAN)
(Delayed Data from NYSE)
$12.90 USD
-0.03 (-0.23%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $12.90 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth B Momentum D VGM
Price, Consensus and EPS Surprise
ELAN 12.90 -0.03(-0.23%)
Will ELAN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ELAN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ELAN
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
Should You Buy, Sell or Hold Merck (MRK) Ahead of Q2 Earnings?
ELAN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Elanco (ELAN) Stock Declines After Sale of Aqua Business
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Merck (MRK) Up 17% YTD on Keytruda Strength: Should You Buy?
Other News for ELAN
Elanco Releases 2023 Environmental, Social and Governance Report, Delivering Healthier Outcomes for Animals, People, Planet and Enterprise
Elanco: Expect Solid Growth From 6 Blockbusters Despite Execution Uncertainty
Elanco Animal Health: Resilience and Strong Growth Prospects Justify Buy Rating
Elanco Confirms Date and Conference Call for Second Quarter 2024 Financial Results Announcement
Argus Research Releases a Hold Rating on Elanco Animal Health (ELAN)